Medicare Enrolled
Dr. Amir Harandi, M.D.
Hematology · Bradenton, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Harandi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Harandi? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Harandi
Dr. Amir Harandi is a hematology in Bradenton, FL, with 20 years in practice. Based on federal Medicare data, Dr. Harandi performed 229,553 Medicare services across 5,719 unique beneficiaries.
Between the years covered by Open Payments, Dr. Harandi received a total of $6,550 from 59 pharmaceutical and/or device companies across 256 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Harandi is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 17% volume in FL$ $6,550 industry payments
Medicare Practice Summary
Medicare Utilization ↗229,553
Medicare services
Top 17% in FL for hematology
5,719
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,478 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 45,900 | $0 | $4 |
| Iron infusion (Injectafer) | 18,000 | $1 | $3 |
| Epoetin alfa injection (Procrit) for anemia | 17,630 | $6 | $23 |
| Anti-nausea injection (aprepitant) | 17,420 | $1 | $5 |
| Pembrolizumab injection (Keytruda) | 14,800 | $43 | $137 |
| Daratumumab injection (Darzalex) | 14,040 | $38 | $110 |
| Nivolumab injection (Opdivo) | 13,080 | $24 | $72 |
| Oxaliplatin chemotherapy injection | 11,986 | $0 | $12 |
| Iron sucrose injection (Venofer) | 11,000 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 10,440 | $18 | $51 |
| Immune globulin infusion (Gammagard) | 6,728 | $36 | $108 |
| Iron infusion (Monoferric) | 6,600 | $17 | $57 |
| Injection, eflapegrastim-xnst, 0.1 mg | 6,336 | $26 | $116 |
| Paclitaxel chemotherapy injection | 5,976 | $0 | $2 |
| Dexamethasone injection (steroid) | 4,223 | $0 | $3 |
| Complete blood count (CBC) with differential | 3,184 | $8 | $29 |
| Blood draw (venipuncture) | 3,182 | $8 | $9 |
| Contrast dye for imaging (iodine-based) | 2,604 | $0 | $1 |
| Office visit, established patient (30-39 min) | 2,006 | $95 | $339 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,720 | $1 | $28 |
| Drug injection, under skin or into muscle | 1,390 | $10 | $69 |
| Epoetin alfa injection (Retacrit) for anemia | 1,140 | $6 | $22 |
| Injection of additional new drug or substance into vein | 1,018 | $12 | $61 |
| Anti-nausea injection (ondansetron/Zofran) | 896 | $0 | $9 |
| Injection, leucovorin calcium, per 50 mg | 725 | $3 | $12 |
| Administration of chemotherapy into vein, 1 hour or less | 616 | $97 | $378 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 581 | $1 | $6 |
| Office visit, established patient (20-29 min) | 567 | $67 | $239 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 559 | $47 | $189 |
| Injection, fluorouracil, 500 mg | 539 | $2 | $7 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 444 | $82 | $642 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 435 | $3 | $205 |
| Injection, zoledronic acid, 1 mg | 358 | $7 | $69 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 338 | $15 | $56 |
| Injection, carboplatin, 50 mg | 305 | $2 | $41 |
| Injection, cisplatin, powder or solution, 10 mg | 276 | $2 | $13 |
| Injection, diphenhydramine hcl, up to 50 mg | 236 | $1 | $3 |
| Administration of chemotherapy into vein, each additional hour | 157 | $21 | $79 |
| Infusion into a vein for hydration, each additional hour | 154 | $10 | $42 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 137 | $53 | $206 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 134 | $137 | $562 |
| New patient office visit (45-59 min) | 122 | $122 | $453 |
| Automated urinalysis | 118 | $2 | $8 |
| Administration of additional new drug or substance into vein, 1 hour or less | 117 | $48 | $178 |
| Office visit, established patient, complex (40-54 min) | 111 | $136 | $474 |
| Infusion, normal saline solution , 1000 cc | 110 | $2 | $7 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 89 | $22 | $84 |
| Injection of drug or substance into vein | 86 | $28 | $156 |
| Injection, magnesium sulfate, per 500 mg | 82 | $1 | $2 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 77 | $16 | $59 |
| Infusion into a vein for hydration, 31-60 minutes | 74 | $24 | $156 |
| Ringers lactate infusion, up to 1000 cc | 72 | $2 | $20 |
| Red blood count automated, with additional calculations | 68 | $5 | $20 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 67 | $124 | $637 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 66 | $24 | $89 |
| Administration of additional new drug or substance into vein using push technique | 65 | $42 | $170 |
| Drawing of blood for a medical problem | 58 | $67 | $277 |
| New patient office visit, complex (60-74 min) | 58 | $167 | $585 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 50 | $15 | $56 |
| Prothrombin time test (blood clotting) | 42 | $4 | $15 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 33 | $3 | $11 |
| Ct scan of chest with contrast | 32 | $53 | $344 |
| CT scan of abdomen and pelvis with contrast | 23 | $177 | $565 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 20 | $401 | $680 |
| New patient office visit (30-44 min) | 19 | $79 | $298 |
| Red blood count, automated test | 18 | $4 | $10 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 16 | $1,098 | $3,706 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
34.3% high complexity
61.4% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,550
Total received (2018-2024)
Avg $936/year across 7 years
Bottom 45% in FL for hematology
59
Companies
256
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,421 (98.0%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$129 (2.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,598
2023$1,689
2022$1,452
2021$613
2020$814
2019$247
2018$137
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Myriad Genetic Laboratories, Inc.
$530
E.R. Squibb & Sons, L.L.C.
$412
PFIZER INC.
$386
AstraZeneca Pharmaceuticals LP
$322
Daiichi Sankyo Inc.
$304
ARRAY BIOPHARMA INC
$301
Gilead Sciences, Inc.
$285
Takeda Pharmaceuticals U.S.A., Inc.
$279
ABBVIE INC.
$266
Janssen Biotech, Inc.
$263
Novartis Pharmaceuticals Corporation
$247
Celgene Corporation
$211
EUSA Pharma (US) LLC
$210
Merck Sharp & Dohme LLC
$204
INTUITIVE SURGICAL, INC.
$172
Medtronic, Inc.
$160
GENZYME CORPORATION
$124
Acerta Pharma LLC
$122
Lilly USA, LLC
$106
Karyopharm Therapeutics Inc.
$89
Amgen Inc.
$85
Merck Sharp & Dohme Corporation
$85
Myovant Sciences Inc.
$81
Janssen Scientific Affairs, LLC
$81
Incyte Corporation
$72
Dendreon Pharmaceuticals LLC
$71
PharmaEssentia USA Corporation
$71
BeiGene USA, Inc.
$71
Sumitomo Pharma America, Inc.
$65
Genentech USA, Inc.
$62
JAZZ PHARMACEUTICALS INC.
$60
Seagen Inc.
$59
Rigel Pharmaceuticals, Inc.
$56
PORTOLA PHARMACEUTICALS, INC.
$56
AbbVie Inc.
$54
Pharmacyclics LLC, An AbbVie Company
$43
Astellas Pharma US Inc
$37
Mirati Therapeutics, Inc.
$36
Kite Pharma, Inc.
$35
ADC Therapeutics America, Inc.
$31
Regeneron Healthcare Solutions, Inc.
$28
Fennec Pharmaceuticals, Inc.
$27
GE HealthCare
$25
G1 Therapeutics, Inc.
$23
Pharmacosmos Therapeutics Inc.
$22
Pharmacyclics LLC, an AbbVie Company
$21
Exelixis Inc.
$21
GlaxoSmithKline, LLC.
$16
Taiho Oncology, Inc.
$16
Acrotech Biopharma Inc.
$16
AMAG Pharmaceuticals, Inc.
$16
Blueprint Medicines Corporation
$15
CTI BioPharma Corp.
$15
TerSera Therapeutics LLC
$15
Acrotech Biopharma LLC
$14
Dova Pharmaceuticals
$14
EMD Serono, Inc.
$14
Octapharma USA, Inc.
$13
Janssen Pharmaceuticals, Inc
$11
Top 3 companies account for 20.3% of total payments
Associated products mentioned in payments ›
ALIMTA · ALUNBRIG · AYVAKIT · Alecensa · BAVENCIO · BELEODAQ · BESREMI · BEVYXXA · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CERDELGA · COSELA · CYRAMZA · DARZALEX · Da Vinci Surgical System · Doptelet · ELAHERE · ELITEK · ELREXFIO · ENHERTU · ENJAYMO · EPKINLY · ERLEADA · Enhertu · Erleada · FERAHEME · FRUZAQLA · Fabhalta · IBRANCE · IMBRUVICA · INLYTA · INREBIC · KEYTRUDA · KISQALI · KRAZATI · LENVIMA · LIBTAYO · LORBRENA · LUPRON DEPOT · LYNPARZA · MEKINIST · MONJUVI · MYRISK · NINLARO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · PADCEV · PROMACTA · PROVENGE · Pedmark · Pomalyst · REBLOZYL · Revlimid · Rezlidhia · SARCLISA · SIGNIA · Sylvant · TAGRISSO · TIVDAK · Tavalisse · Trodelvy · VENCLEXTA · VERZENIO · VOTRIENT · Vonjo · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · XALKORI · XARELTO · XPOVIO · XTANDI · Xospata · Yescarta · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
20
Per 100K population
4.8
County median income
$75,792
Nearest hospital
LAKEWOOD RANCH MEDICAL CENTER
3.4 mi
3.4 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Harandi is a mixed practice specialist, with above-average Medicare volume (top 17% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Harandi experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Harandi performed 45,900 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Harandi receive payments from pharmaceutical companies?
Yes. Dr. Harandi received a total of $6,550 from 59 companies across 256 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Harandi's costs compare to other hematologys in Bradenton?
Dr. Harandi's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Harandi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Bradenton
Browse hematologys in Bradenton ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Myriad Genetic Laboratories, Inc. Payments to Doctors
See all physicians who received payments from Myriad Genetic Laboratories, Inc..
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology